MS - Timely Progression to Natalizumab for greatest possible Benefit

被引：0
|
作者：
不详
机构：
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2013年 / 81卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [1] Drug-induced PML greatest with natalizumab for MS
    Reactions Weekly, 2024, 1995 (1) : 11 - 11
  • [2] Timely Escalation to Natalizumab
    Ameri, Abdol A.
    NERVENHEILKUNDE, 2012, 31 (7-8) : 560 - 561
  • [3] The effects of natalizumab monotherapy on multiple measures of disability progression in MS patients
    Phillips, JT
    Kappos, L
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Miller, DH
    Polman, CH
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Lynn, F
    Panzara, MA
    Sandrock, AW
    NEUROLOGY, 2006, 66 (05) : A62 - A63
  • [4] For the greatest benefit to humankind
    不详
    NATURE COMPUTATIONAL SCIENCE, 2021, 1 (11): : 705 - 706
  • [5] For the greatest benefit to humankind
    Nature Computational Science, 2021, 1 : 705 - 706
  • [6] Possible prognostic factors of MS progression in children
    Skripchenko, E.
    Skripchenko, N.
    Syrovtseva, A.
    Ivanova, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E318 - E318
  • [7] Clinical efficacy and benefit of natalizumab
    Coyle, Patricia K.
    Jeffery, Douglas R.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 : S7 - S15
  • [8] Progression of Whole Brain and Gray Matter Atrophy in Relapsing MS Despite Treatment with Natalizumab
    Sieved, Adil
    Arndt, Nancy
    Reder, Anthony
    NEUROLOGY, 2017, 88
  • [9] Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT
    Fitzgerald, Kathryn
    Munger, Kassandra
    Freedman, Mark
    Hartung, Hans
    Montalban, Xavier
    Edan, Gilles
    Barkhof, Frederik
    Radue, Ernst-Wilhelm
    Kappos, Ludwig
    Suarez, Gustavo
    Ascherio, Alberto
    NEUROLOGY, 2016, 86
  • [10] The second greatest benefit to mankind?
    Chantler, C
    LANCET, 2002, 360 (9348): : 1870 - 1877
12345